(NASDAQ: ACIU) Ac Immune Sa's forecast annual revenue growth rate of 198.63% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.49%, and it is also forecast to beat the US market's average forecast revenue growth rate of 14.23%.
Ac Immune Sa's revenue in 2026 is $4,746,153.On average, 6 Wall Street analysts forecast ACIU's revenue for 2026 to be $4,145,588,944, with the lowest ACIU revenue forecast at $323,133,326, and the highest ACIU revenue forecast at $9,732,153,106. On average, 6 Wall Street analysts forecast ACIU's revenue for 2027 to be $9,904,402,703, with the lowest ACIU revenue forecast at $0, and the highest ACIU revenue forecast at $20,565,157,152.
In 2028, ACIU is forecast to generate $12,187,701,851 in revenue, with the lowest revenue forecast at $6,381,272,728 and the highest revenue forecast at $18,256,625,931.